(Q43035939)

English

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.

scientific article published in April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

William D. Rawlinson

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

object named as

Gregory J Dore

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

William Sievert

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Geoffrey W McCaughan

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Motoko Yoshihara

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Darrell H Crawford

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wendy Cheng

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Martin Weltman

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Bishoy Rizkalla

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Jean K Depamphilis

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Stuart K Roberts

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

CHARIOT Study Group

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1109-1117

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Factors contributing to ribavirin-induced anemia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Pharmacokinetics of ribavirin in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24180

21 January 2018

Identifiers

10.1002/HEP.24180

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43035939&oldid=1797602426"